Pediatr. praxi. 2024;25(3):161-164 | DOI: 10.36290/ped.2024.033

Current treatment options of diabetes mellitus type 1 in pediatric population

MUDr. Petr Polák, doc. MUDr. Renata Pomahačová, Ph.D., MUDr. Karel Fiklík, MUDr. Petra Paterová, prof. MUDr. Josef Sýkora, Ph.D.
Dětská klinika Fakultní nemocnice v Plzni, Univerzita Karlova, Lékařská fakulta v Plzni

The world-wide increasing incidence of this autoimunne disease, new types of short-acting insulin analogues and the improvement of the use of modern technologies, such as continuous glucose monitoring and the closed-loop hybrid insulin pump algorithm, lead to an improvement in the overal care of diabetics and a better long-term compensation of the underlying disease. The review article tries to summarize the current trends in the treatment of diabetes mellitus type I in the pediatric population and point out its possible complications. Key words: diabetes mellitus type 1, insulin, continuous glucose monitoring, insulin pumps.

Keywords: diabetes mellitus 1. typu, inzulin, kontinuální monitorace glykemie, inzulinové pumpy.

Accepted: June 12, 2024; Published: June 14, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Polák P, Pomahačová R, Fiklík K, Paterová P, Sýkora J. Current treatment options of diabetes mellitus type 1 in pediatric population. Pediatr. praxi. 2024;25(3):161-164. doi: 10.36290/ped.2024.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2021;44(11): 2589-2625. Go to original source... Go to PubMed...
    2. Libman I, Haynes A, Lyons S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1160-1174. Go to original source... Go to PubMed...
    3. Šumník Z, Konečná P, Venháčová P, et al. Continuing improvement in metabolic control in Czech children with type 1 diabetes: data from the ČENDA registry (2013-2020). Čes-slov Pediat. 2022;77(2):64-71.
    4. Petruželková L, Plachý L, Kajprová M, et al. The implementation of modern technology into standard of care of type 1 diabetes. Čes-slov Pediat. 2022;77(2):78-85. Go to original source...
    5. Ogle GD, James S, Dabelea D, et al. Global estimates of incidence of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Atlas, 10th edition. Diabetes Res Clin Pract. 2022;183.Další literatura u autora a na www.pediatriepropraxi.cz Go to original source...
    6. Karvonen M, Viik-Kajander M, Moltchanova E, et al. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care. 2000;23(10): 1516-1526. Go to original source... Go to PubMed...
    7. de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276. Go to original source... Go to PubMed...
    8. Yoo JH, Kim JH. Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control. Diabetes Metab J. 2023;47(1):27-41. Go to original source... Go to PubMed...
    9. Tauschmann M, Forlenza G, Hood K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring. Pediatr Diabetes. 2022;23(8):1390-1405. Go to original source... Go to PubMed...
    10. Bjornstad P, Dart A, Donaghue KC, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Microvascular and macrovascular complications in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1432-1450. Go to original source... Go to PubMed...
    11. Marzelli MJ, Mazaika PK, Barnea-Goraly N, et al. Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes. 2014;63(1):343-353. Go to original source... Go to PubMed...
    12. Cengiz E, Danne T, Ahmad T, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8): 1277-1296. Go to original source... Go to PubMed...
    13. Parkin CG, Graham C, Smolskis J. Continuous Glucose Monitoring Use in Type 1 Diabetes: Longitudinal Analysis Demonstrates Meaningful Improvements in HbA1c and Reductions in Health Care Utilization. J Diabetes Sci Technol. 2017;11(3):522-528. Go to original source... Go to PubMed...
    14. Šumník Z, Petruželková L, Koloušková S, et al. Moderní technologie v terapii diabetu 1. typu v dětském věku. Čes-slov Pediat. 2019;74(1):5-10.
    15. Fröhlich-Reiterer E, Elbarbary NS, Simmons K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Other complications and associated conditions in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2022;23(8):1451-1467. Go to original source... Go to PubMed...
    16. Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. Pediatr Diabetes. 2022;23(8):1406-1431. Go to original source... Go to PubMed...
    17. Adolfsson P, Hartvig NV, Kaas A, et al. Increased Time in Range and Fewer Missed Bolus Injections after Introduction of a Smart Connected Insulin Pen. Diabetes Technol Ther. 2020;22(10):709-718. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.